Actively Recruiting
Phase 3 Randomized Study of JNJ-101556143 With Best Supportive Care Versus Placebo in Men With Metastatic Androgen-Resistant Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
400
Participants Needed
4
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying metastatic androgen pathway modulation-resistant prostate cancer mAPMR, an advanced form of prostate cancer that no longer responds to hormone treatments and has spread to other parts of the body. This trial aims to evaluate how well JNJ-101556143 plus Best Supportive Care improves overall survival compared with placebo plus Best Supportive Care in affected participants. Participants will be randomly assigned to receive either JNJ-101556143 or a matching placebo, both taken orally once daily alongside Best Supportive Care. Best Supportive Care may include treatments such as palliative radiation, low dose steroids, pain medications, bone sparing agents, and other clinically indicated procedures. Treatment will continue until specific discontinuation criteria are met. During the study, participants will be monitored for overall survival up to 21 months. Researchers will also assess radiographic progression-free survival, time to symptomatic progression, skeletal-related events, pain progression, and treatment-related adverse events. Plasma concentrations of the study drug will be measured during the first four treatment cycles. Safety and laboratory tests will be conducted regularly throughout the participation period, which lasts until the studys completion in 2028.
CONDITIONS
Brief Title
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here